Abstract Number: 2164 • 2015 ACR/ARHP Annual Meeting
Burden of Symptomatic Knee Osteoarthritis in the United States: Impact of Race/Ethnicity, Age and Sex
Background/Purpose : Growing evidence suggests that the prevalence and incidence of knee OA is rising, partially due to increasing life expectancy and the growing obesity…Abstract Number: 2165 • 2015 ACR/ARHP Annual Meeting
Awareness and Reasons for Lack of Post-Fracture Osteoporosis Therapy: A Survey of Post-Menopausal Women
Background/Purpose: Osteoporotic fractures cause patient morbidity and increase risk for future fracture. Effective drug therapies for osteoporosis (OP) are available, yet only a minority of…Abstract Number: 2166 • 2015 ACR/ARHP Annual Meeting
Work Productivity in Newly Diagnosed, Untreated Rheumatoid Arthritis Patients
Background/Purpose:Rheumatoid arthritis (RA) is a known cause of work productivity loss. The goal within rheumatology today is to diagnose RA as soon as possible, to…Abstract Number: 2167 • 2015 ACR/ARHP Annual Meeting
Application of Combined Reporting of Benefit and Harm (OMERACT 3×3 methodology) to the Rheumatoid Arthritis Comparison of Active Therapies Trial
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Initiative has suggested an analysis of the occurrence of benefit and harm in trials simultaneously, at the individual…Abstract Number: 2168 • 2015 ACR/ARHP Annual Meeting
The Smoking Paradox in the Development of Myocardial Infarction Among Rheumatoid Arthritis Patients
Background/Purpose: Smoking is a strong risk factor for myocardial infarction (MI), but not among rheumatoid arthritis (RA) patients. These paradoxical findings may be due to…Abstract Number: 2169 • 2015 ACR/ARHP Annual Meeting
Low Education Is Associated with Mortality Among Individuals with Knee and/or Hip OA: The Johnston County Osteoarthritis Project
Background/Purpose: Low socioeconomic status (SES) is associated with an increased risk of death as well as knee and/or hip osteoarthritis (OA). SES and mortality has…Abstract Number: 2170 • 2015 ACR/ARHP Annual Meeting
Sleep Efficiency and Cardiovascular Risk Burden in Rheumatoid Arthritis
Background/Purpose: Sleep is an important physiological process responsible for regulating several metabolic and hormonal processes; hence, poor sleep may negatively impact health. Reduced sleep duration…Abstract Number: 2171 • 2015 ACR/ARHP Annual Meeting
A Comparison of Maternal Outcomes in Women with and without Juvenile Idiopathic Arthritis
Background/Purpose: Although there is a higher frequency of adverse maternal outcomes in mother with rheumatoid arthritis, little is known regarding mothers with juvenile idiopathic arthritis…Abstract Number: 2172 • 2015 ACR/ARHP Annual Meeting
Distribution of Clinical Osteoarthritis and Associations to Health-Related Quality of Life in a Population-Based Osteoarthritis Cohort
Background/Purpose: Osteoarthritis (OA) is a major cause of musculoskeletal pain and disability, and is commonly reported to impair health-related quality of life (HRQoL). We aimed…Abstract Number: 2173 • 2015 ACR/ARHP Annual Meeting
Impact of Smoking on Patient-Reported Disease Status and Symptoms Among Women with Lupus
Background/Purpose: Smoking appears to be associated both with an increased risk of rheumatoid arthritis and with more severe symptoms. The impact of smoking on patient-reported…Abstract Number: 2174 • 2015 ACR/ARHP Annual Meeting
Neutrophils in Primary Antiphospholipid Syndrome Are Characterized By a Prominent Activated Phenotype and Uniquely Remodeled Chromatin Architecture
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by recurrent thrombotic events, pregnancy complications, and the presence of antiphospholipid antibodies. The pathogenesis of…Abstract Number: 2175 • 2015 ACR/ARHP Annual Meeting
Comparative Study Between Coagucheck XS Versus Standard Laboratory Practice Protrombine Time for Monitoring Anticoagulant Therapy in Patients with Antiphospholipid Syndrome
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune disease characterized by antiphospholipid antibodies (aPL) associated with thrombosis and/or pregnancy morbidity. Although initially described in patients with systemic lupus erythematosus (SLE) it…Abstract Number: 2176 • 2015 ACR/ARHP Annual Meeting
The Ability of Recombinant Domain I of Beta-2-Glycoprotein I to Inhibit Lupus Anticoagulant Effect of IgG from Patients with APS Is Enhanced By Pegylation
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical events including vascular thrombosis (VT) and pregnancy morbidity (PM).…Abstract Number: 2177 • 2015 ACR/ARHP Annual Meeting
Pegylated Recombinant Domain I of Beta-2-Glycoprotein I, a Potential Therapeutic Agent for Antiphospholipid Syndrome, Fully Retains Its Ability to Inhibit Binding of IgG or IgA Antibodies from Patients with APS to Beta-2-Glycoprotein I in Vitro
Background/Purpose: Antiphospholipid Syndrome (APS) is an autoimmune rheumatic disorder in which antiphospholipid antibodies (aPL) cause clinical events including vascular thrombosis (VT) and pregnancy morbidity (PM).…Abstract Number: 2178 • 2015 ACR/ARHP Annual Meeting
Oxidation of beta2-Glycoprotein I (beta2-GPI) Associates with the Presence of Antibodies to Domain I of beta2-GPI in Patients with the Antiphospholipid Syndrome but Is Not Affected By the Antibodies in Vivo in a Rat Model
Background/Purpose: β2GPI represents the major antigenic target for antiphospholipid antibodies (aPL), the hallmark of antiphospholipid syndrome (APS). β2GPI contains five homologous domains, with domain I…
ACR Meeting Abstracts